Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $10.50

Agenus Inc. (NASDAQ:AGEN) has been assigned an average rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.50.

AGEN has been the subject of a number of research analyst reports. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Robert W. Baird lowered shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $8.00 in a research report on Friday, July 19th. B. Riley dropped their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $7.00 price target (up previously from $3.00) on shares of Agenus in a report on Friday, July 19th. Finally, William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th.

Institutional Trading of Agenus

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC boosted its position in Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares in the last quarter. Pennant Investors LP acquired a new stake in shares of Agenus during the 4th quarter worth approximately $389,000. Virtu Financial LLC acquired a new stake in shares of Agenus during the 4th quarter worth approximately $213,000. Finally, Key Client Fiduciary Advisors LLC increased its holdings in shares of Agenus by 38.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 858,969 shares of the biotechnology company’s stock valued at $498,000 after purchasing an additional 236,500 shares in the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Stock Up 5.6 %

NASDAQ AGEN opened at $6.26 on Friday. Agenus has a 52 week low of $4.41 and a 52 week high of $27.20. The company has a 50 day moving average price of $7.24 and a 200 day moving average price of $10.59. The firm has a market cap of $135.03 million, a PE ratio of -0.49 and a beta of 1.36.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same quarter in the prior year, the company earned ($4.00) earnings per share. On average, equities research analysts anticipate that Agenus will post -10.87 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.